Patents Examined by Jennifer A Benavides
  • Methods for treating or preventing SARS-CoV-2 infections and COVID-19 with anti-SARS-CoV-2 spike glycoprotein antibodies
    Patent number: 11999777
    Abstract: The present invention provides methods for preventing and treating SARS-CoV-2 infections, COVID-19, or symptoms thereof. The methods of the invention feature the administration of one or more antigen-binding molecules (e.g., antibodies) that bind a surface protein of SARS-CoV-2 (e.g., spike protein).
    Type: Grant
    Filed: June 2, 2021
    Date of Patent: June 4, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Samit Ganguly, Jennifer Hamilton, Gary Herman, Andrea Hooper, Flonza Isa, Meagan O'Brien, Sumathi Sivapalasingam, Kenneth Turner, Eduardo Forleo Neto
  • Compositions and methods of treating facioscapulohumeral muscular dystrophy
    Patent number: 11999955
    Abstract: Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating Facioscapulohumeral muscular dystrophy.
    Type: Grant
    Filed: November 4, 2022
    Date of Patent: June 4, 2024
    Assignee: AVIDITY BIOSCIENCES, INC.
    Inventors: Barbora Malecova, Rob Burke, David Sala Cano, Beatrice Diana Darimont
  • Anti-TMPRSS2 antibodies and antigen-binding fragments
    Patent number: 11999799
    Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to TMPRSS2 and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections or influenza virus infections).
    Type: Grant
    Filed: February 9, 2021
    Date of Patent: June 4, 2024
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Alina Baum, Christos Kyratsous, Lisa Purcell
  • Anti-PD-L1 antibody and use thereof
    Patent number: 11993655
    Abstract: An antibody that binds to the PD-L1 protein or CD137 protein, an antigen-binding fragment or a variant thereof, as well as a bispecific antibody that can bind to both the PD-L1 protein and the CD137 protein. The bispecific antibody has a strong ability to specifically recognize the PD-L1 protein and the CD137 protein, and can enhance T-cell activity. The antibody or the antigen-binding fragment or the variant thereof and the bispecific antibody may be used in the prevention and treatment of tumors.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: May 28, 2024
    Assignee: Oricell Therapeutics Co., Ltd.
    Inventors: Bohua Li, Huajing Wang, Xiaowen He
  • Single-domain antibodies against LAG-3 and uses thereof
    Patent number: 11958903
    Abstract: The present application provides anti-LAG-3 constructs comprising a single-domain antibody (sdAb) that specifically recognizes LAG-3. Also provided are methods of making and using these constructs.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: April 16, 2024
    Assignee: Nanjing Legend Biotech Co., Ltd.
    Inventors: Wang Zhang, Shuai Yang, Shu Wu, Chuan-Chu Chou
  • Compositions comprising a variant polypeptide and uses thereof
    Patent number: 11946045
    Abstract: The present invention relates to variant polypeptides, methods of preparing the variant polypeptides, processes for characterizing the variant polypeptides, compositions and cells comprising the variant polypeptides, and methods of using the variant polypeptides. The invention further relates to complexes comprising the variant polypeptides, methods of producing the complexes, processes for characterizing the complexes, cells comprising the complexes, and methods of using the complexes.
    Type: Grant
    Filed: December 30, 2022
    Date of Patent: April 2, 2024
    Assignee: Arbor Biotechnologies, Inc.
    Inventors: Shaorong Chong, Wei-Cheng Lu, Brendan Jay Hilbert, Quinton Norman Wessells, Lauren E. Alfonse, Anthony James Garrity
  • Bispecific PD-1 and TIGIT binding proteins and uses thereof
    Patent number: 11939382
    Abstract: The disclosure relates to binding proteins, including antibodies, that bind to Programmed Death-1 (“PD-1”) and T cell immunoreceptor with Ig and ITIM domains (“TIGIT”). The disclosure also provides compositions comprising such binding proteins and nucleic acid molecules encoding such binding proteins. The disclosure further relates to methods of treating a disorder or condition using such binding proteins.
    Type: Grant
    Filed: April 29, 2022
    Date of Patent: March 26, 2024
    Assignee: MedImmune, LLC
    Inventors: Yariv Mazor, Yue Wang, Gordon Moody, Deepali Malhotra, Michael Overstreet, Eleanor Clancy-Thompson, Karin Lee, Stacy Pryts, Scott Hammond
  • Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and T cell receptor
    Patent number: 11932702
    Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from cancer. Specifically, the technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that one ISVD binds to TCR and at least two ISVDs bind to GPC3. The present technology also provides nucleic acids, vectors and compositions.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: March 19, 2024
    Assignees: Ablynx N.V., Sanofi
    Inventors: Daniel Janssen, Carlo Boutton, Evelyne Dombrecht, Bram Laukens, Paolo Meoni, Lily Pao, Jan Pype, Peter Schotte, Benedikte Serruys, Ana Paula Vintem, Diane Van Hoorick
  • Mesothelin-targeted CD40 agonistic multispecific antibody constructs for the treatment of solid tumors
    Patent number: 11926672
    Abstract: The present invention relates to a human agonistic CD40 multispecific antibody construct for treatment of solid tumors by engineering a molecule that specifically targets the CD40 pathway on tumor-associated APCs, without systemic CD40 activation.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: March 12, 2024
    Assignee: Amgen Inc.
    Inventors: Xin Yu, Jackson Egen, Fernando Garces, Shunsuke Takenaka, AeRyon Kim, Deepali Sawant
  • Human antibodies to artemin and methods of use thereof
    Patent number: 11926661
    Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind to human artemin. Methods for using anti-artemin antibodies and antigen-binding fragments are also provided.
    Type: Grant
    Filed: April 19, 2022
    Date of Patent: March 12, 2024
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Susan D. Croll, Lynn MacDonald, Andrew J. Murphy
  • Antibodies binding TNFR2 and uses thereof
    Patent number: 11912777
    Abstract: The present invention relates to a novel antibody and antibody fragment that specifically binds to TNFR2 and to a composition comprising said antibody or antibody fragment. In addition, the present invention relates to a nucleic acid encoding the antibody or an antibody fragment thereof and a host cell comprising the same, and to a related use thereof. Besides, the present invention relates to the use of the antibody and antibody fragment for treatment and diagnosis.
    Type: Grant
    Filed: December 9, 2022
    Date of Patent: February 27, 2024
    Assignee: Nanjing Leads Biolabs Co., Ltd.
    Inventors: Xiaoqiang Kang, Shoupeng Lai, Xiao Huang, Huan Lin, Yujia Dang
  • Antibodies or antigen-binding fragments that bind to OX40
    Patent number: 11879015
    Abstract: The present disclosure provides antibodies that bind to OX40 and antigen binding fragments thereof, and use of the antibodies and the antigen binding fragments in the treatment of diseases for example cancers. The antibodies or the antigen binding fragments include a heavy chain variable region including one or more CDRs having an amino acid sequence selected from amino acid sequences as set forth in SEQ ID NOs: 1-12.
    Type: Grant
    Filed: April 29, 2022
    Date of Patent: January 23, 2024
    Assignee: BIODURO (BEIJING) CO., LTD.
    Inventors: Xiang Li, Guoqian Sun, Chenguang Cai, Shiying Fu, Ting Yang, Shuang Zhao, Ying Li, Xinyue Dai, Qi Sun, Fengzhi Zhang, Youyou Lin, Yu Chen, Zhengfei Xue, Hui Pang, Ying Bai, Shin-chen Hou
  • Anti-MUC1 antibody-drug conjugate
    Patent number: 11872289
    Abstract: The present invention pertains to novel antibody drug conjugates (ADC) comprising anti-MUC1 antibody. In particular, said ADC showed significant anti-tumor efficacy.
    Type: Grant
    Filed: August 1, 2022
    Date of Patent: January 16, 2024
    Assignee: DAIICHI SANKYO CO., LTD.
    Inventors: Johanna Gellert, Anke Flechner, Doreen Weigelt, Antje Danielczyk, Akiko Nagase
  • Combination therapy of PD-1-targeted IL-2 variant immunocytokines and antibodies against human PD-L1
    Patent number: 11865082
    Abstract: The present invention relates to the combination therapy of specific PD-1-targeted IL-2 variant immunocytokines with specific antibodies which bind human PD-L1.
    Type: Grant
    Filed: September 1, 2021
    Date of Patent: January 9, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Laura Codarri Deak, Douglas Hanahan, Christian Klein, Valeria Nicolini, Pablo Umana, Stephan Wullschleger
  • Engineered anti-IL-2 antibodies
    Patent number: 11851485
    Abstract: Described herein are engineered anti-IL-2 antibodies with modified amino acid sequences. The engineered antibodies would confer modified receptor binding specificity to an IL-2-anti-IL2 antibody complex, inhibiting the binding of IL-2 to CD25. The engineered anti-IL-2 antibodies would facilitate expansion of subsets of effector immune cells and decrease undesirable effects caused by IL-2. Thus, the engineered anti-IL-2 antibodies would be useful in treating disease such as cancer and infection.
    Type: Grant
    Filed: November 16, 2022
    Date of Patent: December 26, 2023
    Assignee: AULOS BIOSCIENCE, INC.
    Inventors: Inbar Amit, Itay Levin, Guy Nimrod, Sharon Fischman, Reut Barak Fuchs, Marek Strajbl, Timothy Wyant, Michael Zhenin, Olga Bluvshtein Yermolaev, Yehezkel Sasson, Noam Grossman, Natalia Levitin, Yanay Ofran
  • Anti-transferrin receptor antibody and uses thereof
    Patent number: 11839660
    Abstract: Aspects of the disclosure relate to antibodies that bind to transferrin receptor (e.g., transferrin receptor 1) and complexes comprising the antibody covalently linked to a molecular payload. Methods of using the antibodies are also provided.
    Type: Grant
    Filed: March 10, 2023
    Date of Patent: December 12, 2023
    Assignee: Dyne Therapeutics, Inc.
    Inventors: Romesh R. Subramanian, Mohammed T. Qatanani, Timothy Weeden, Cody A. Desjardins, Brendan Quinn, John Najim
  • Antibody cocktail against SARS-CoV-2 spike protein
    Patent number: 11834493
    Abstract: Provided herein are antibodies that are useful for treating SARS-CoV-2 infections in a subject. Also provided herein are compositions comprising one or more antibodies, methods of treatment comprising administering one or more antibodies, and kits comprising one or more antibodies.
    Type: Grant
    Filed: January 4, 2022
    Date of Patent: December 5, 2023
    Assignee: IMMUNOME, INC.
    Inventors: Matthew K. Robinson, Pavel Nikitin, Michael John Morin, Jillian Dimuzio, Ray Howanski, John P. Dowling
  • Antibodies for binding pathologic forms of calcineurin
    Patent number: 11827718
    Abstract: Provided herein are antibodies, or antigen-binding portions thereof, which specifically bind to pathologic forms of calcineurin. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and methods for use of these antibodies.
    Type: Grant
    Filed: May 19, 2021
    Date of Patent: November 28, 2023
    Assignee: University of Kentucky Research Foundation
    Inventors: Susan D. Kraner, Rodney P Guttmann, Christopher M. Norris, Jenna Leigh Gollihue
  • Antibody capable of blocking CD47-SIRPa interaction and application thereof
    Patent number: 11820820
    Abstract: An antibody capable of blocking CD47-SIRPa interaction and an application thereof.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: November 21, 2023
    Assignee: CHENGDU CONMED BIOSCIENCES CO., LTD.
    Inventors: Bo Chen, Gang Xu, Xuhong Chen, Feng Li, Boyan Zhang, Sijia Huang
  • ILT-binding agents and methods of use thereof
    Patent number: 11802155
    Abstract: The present disclosure provides binding agents, such as antibodies, that specifically bind ILT2, ILT4, or both ILT2 and ILT4, as well as compositions comprising the binding agents, and methods of their use. The disclosure also provides related polynucleotides and vectors encoding the binding agents and cells comprising the binding agents.
    Type: Grant
    Filed: April 29, 2021
    Date of Patent: October 31, 2023
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Dana Yen Mei Duey, Allen James Ebens, Jr., Daniel David Kaplan, Chia-Ying Kao Lam, Kalyani Mondal, Geoffrey William Stone, Yan Wang